Preprint Article Version 2 Preserved in Portico This version is not peer-reviewed

Therapeutic Approach for Global Myocardial Injury Using Bone Marrow-Derived Mesenchymal Stem Cells by Cardiac Support Device in Rats

Version 1 : Received: 10 April 2020 / Approved: 15 April 2020 / Online: 15 April 2020 (03:32:24 CEST)
Version 2 : Received: 23 April 2020 / Approved: 24 April 2020 / Online: 24 April 2020 (04:34:11 CEST)
Version 3 : Received: 7 September 2020 / Approved: 7 September 2020 / Online: 7 September 2020 (07:30:47 CEST)

How to cite: Liu, Z.; Naveed, M.; Baig, M.M.F.A.; Mikrani, R.; Li, C.; Dar, K.; Saeed, M.; Zhan, Q.; Ahmed, B.; Zhou, X. Therapeutic Approach for Global Myocardial Injury Using Bone Marrow-Derived Mesenchymal Stem Cells by Cardiac Support Device in Rats. Preprints 2020, 2020040227 (doi: 10.20944/preprints202004.0227.v2). Liu, Z.; Naveed, M.; Baig, M.M.F.A.; Mikrani, R.; Li, C.; Dar, K.; Saeed, M.; Zhan, Q.; Ahmed, B.; Zhou, X. Therapeutic Approach for Global Myocardial Injury Using Bone Marrow-Derived Mesenchymal Stem Cells by Cardiac Support Device in Rats. Preprints 2020, 2020040227 (doi: 10.20944/preprints202004.0227.v2).

Abstract

Bone marrow-derived mesenchymal stem cells (BMSCs) have been considered a promising therapeutic approach to cardiovascular disease. This study intends to compare the effect of BMSCs through a standard active cardiac support device (ASD) and intravenous injection on global myocardial injury induced by isoproterenol. BMSCs were cultured in vitro, and the transplanted cells were labeled with a fluorescent dye CM-Dil. Isoproterenol (ISO) was injected into the rats; two weeks later, the labeled cells were transplanted into ISO-induced heart injury rats through the tail vein and ASD device for five days. The rats were sacrificed on the first day, the third day, and the fifth day after transplantation to observe the distribution of cells in the myocardium by fluorescence microscopy. The hemodynamic indexes of the left ventricle were measured before sacrificing. H&E staining and Masson’s trichrome staining were used to evaluate the cardiac histopathology. In the ASD groups, after three days of transplantation, there were a large number of BMSCs on the epicardial surface, and after five days of transplantation, BMSCs were widely distributed in the ventricular muscle. But in the intravenous injection group, there were no labeled-BMSCs distributed. In the ASD+BMSCs-three days treated group and ASD+BMSCs -five days-treated group, left ventricular systolic pressure (LVSP), maximum rate of left ventricular pressure rise (+dP/dt), maximum rate of left ventricular pressure decline (-dP/dt) increased compared with model group and intravenous injection group (P<0.05). By giving BMSCs through ASD device, cells can rapidly and widely are distributed in the myocardium and significantly improve heart function.

Subject Areas

global myocardial injury; BMSCs; active cardiac support device (ASD); stem cell treatment; epicardial delivery

Comments (1)

Comment 1
Received: 24 April 2020
Commenter: Muhammad Naveed
Commenter's Conflict of Interests: Author
Comment: Authorship changed
+ Respond to this comment

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 1
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.